Consolidated Statements of Operations (Unaudited) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Revenues:
Product sales	$ 54,011	$ 43,663	$ 141,529	$ 120,739
Contracts and grants	12,581	15,099	45,753	44,697
Total revenues	66,592	58,762	187,282	165,436
Operating expenses:
Cost of product sales	10,230	10,706	30,927	27,843
Research and development	27,390	29,216	84,281	95,456
Selling, general and administrative	19,155	17,432	56,542	56,028
Impairment of in-process research and development	0	0	9,600	0
Income (loss) from operations	9,817	1,408	5,932	(13,891)
Other income (expense):
Interest income	55	22	103	81
Interest expense	0	0	0	0
Other income (expense), net	(16)	37	1,745	(9)
Total other income (expense)	39	59	1,848	72
Income (loss) before provision for (benefit from) income taxes	9,856	1,467	7,780	(13,819)
Provision for (benefit from) income taxes	4,236	1,604	4,639	(3,032)
Net income (loss)	5,620	(137)	3,141	(10,787)
Net loss attributable to noncontrolling interest	997	1,686	4,276	5,149
Net income (loss) attributable to Emergent BioSolutions Inc.	$ 6,617	$ 1,549	$ 7,417	$ (5,638)
Income (loss) per share - basic	$ 0.18	$ 0.04	$ 0.21	$ (0.16)
Income (loss) per share - diluted	$ 0.18	$ 0.04	$ 0.20	$ (0.16)
Weighted-average number of shares - basic	36,202,801	35,855,217	36,144,242	35,552,900
Weighted-average number of shares - diluted	36,670,094	36,447,933	36,424,630	35,552,900